PeproMene Reports Durable Responses With BAFF-R CAR T
Irvine, California, U.S., September 8, 2026 PeproMene Bio, Inc. has announced publication in The Lancet of results from a...
Belite Bio
Advertisement
Belite Bio Files Japan NDA for Tinlarebant in Stargardt Disease
San Diego, California, U.S., September 8, 2026 Belite Bio has announced the submission of a New Drug Application (NDA)...
Senhwa Advances CX-5461 in Photoimmunotherapy Research
TAIWAN, August 12, 2026 Senhwa Biosciences, Inc. has announced new research findings involving its investigational cancer drug Pidnarulex (CX-5461),...
Belite Bio Wins FDA Priority Review for Tinlarebant NDA
SAN DIEGO, California, August 11, 2026 Belite Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Belite Bio Reports Positive Phase 3 Tinlarebant Data at ASRS 2026
SAN DIEGO, July 20, 2026 Belite Bio, Inc. (NASDAQ: BLTE) announced additional positive secondary endpoint data from its Phase...
Advertisements
Belite Bio Highlights DRAGON Trial at ISCEV and ASRS
SAN DIEGO, July 6, 2026 Belite Bio announced that new clinical data from its Phase 3 DRAGON trial evaluating...
Tinlarebant Phase 3 Trial Marks Major Breakthrough for STGD1
San Diego, December 1, 2025 — Belite Bio has announced positive topline results from the pivotal global Phase 3...
Advertisement
